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Abstract
Background Dabigatran etexilate is a pro-drug of the oral
reversible direct thrombin inhibitor dabigatran that inter-
acts with the active site in the catalytic domain of the
thrombin molecule.
Objective To assess the electrophysiological effects of
therapeutic and supratherapeutic doses of dabigatran
etexilate in healthy subjects, a thorough QT study was
performed.
Methods In this single-centre, blinded, placebo- and
active-controlled, four-period, crossover study, 40 healthy
Caucasian subjects (20 women and 20 men) received single
oral doses of dabigatran etexilate (150 mg and 600 mg),
moxifloxacin 400 mg (positive control) or placebo, in a
randomized order. Electrocardiogram (ECG) profiles were
recorded at baseline and during the randomized study
treatment in each period. The individually heart-rate–
corrected QT interval (QTcI) was the primary parameter.
The primary endpoint was the mean of these QTcI values
obtained at 1.5, 2 and 3 h following study drug adminis-
tration minus the mean of the time-matched QTcI values
obtained at baseline day -1. The hypothesis tested was that
the difference between each of the two doses of dabigatran
etexilate (150 mg and 600 mg) and placebo, for the mean
time-matched change from baseline (CfB) of QTcI
between 1.5 and 3 h (the primary endpoint), was greater
than or equal to 10 ms. Secondary endpoints were the time-
matched CfB of QTcI between 0.5 and 24 h post-dose.
Results All subjects completed the study without pre-
mature discontinuation and all treatments were well toler-
ated. Following dabigatran etexilate administration, the
mean values of the placebo-adjusted time-matched CfB of
QTcI between 1.5 and 3 h post-dose were close to 0; the
upper bound of the two-sided 90 % confidence interval
(CI) was 1.4 ms for dabigatran etexilate 150 mg and 1.3 ms
for dabigatran etexilate 600 mg. The placebo-adjusted
time-matched CfB of QTcI remained close to 0 at all time
points, and all 90 % CIs were between -5 ms and 5 ms,
well below the pre-defined non-inferiority margin of 10 ms.
Conclusion This thorough QT study demonstrated that
therapeutic and fourfold supratherapeutic doses of dabig-
atran etexilate do not prolong QT intervals.
1 Introduction
Vitamin K antagonists (VKAs), such as warfarin, and
injectable anticoagulants, including heparins, have been the
cornerstone of anticoagulant therapy for decades. However,
VKAs have a narrow therapeutic window, numerous drug
and food interactions, and require routine monitoring and
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dose adjustments [1]. Heparins require parenteral admin-
istration, which can be difficult when chronic use is
required [2, 3].
Dabigatran etexilate is an oral pro-drug, which is rapidly
converted to dabigatran, a direct thrombin inhibitor [4].
Dabigatran has predictable pharmacokinetic (PK) and
pharmacodynamic properties, is predominantly excreted
renally and has a half-life of 12–17 h [4, 5]. It does not
require anticoagulation monitoring or multiple dose
adjustments [6]. Dabigatran etexilate has a similar safety
and efficacy profile to enoxaparin sodium for the preven-
tion of venous thromboembolism (VTE) after knee or hip
replacement [7–11]. Furthermore, dabigatran etexilate 150
mg twice daily shows superiority to warfarin in moderate
to high risk patients with non-valvular atrial fibrillation
(AF) in reducing the risk of stroke (ischaemic and haem-
orrhagic) and systemic embolism and intracranial haem-
orrhage, without an increase in major bleeding [7, 12–15].
Drugs may induce QT prolongation, which can result in
adverse cardiac events [16]. The QT interval indirectly
represents ventricular depolarization and subsequent re-
polarization; prolonged QT intervals can increase the risk
of cardiac pro-arrhythmias such as torsade de pointes,
which may result in sudden death [16].
To our knowledge, there are no previously published
evaluations of the effect of dabigatran on cardiac repolar-
ization that are considered compliant with regulatory
standards [International Conference on Harmonisation
(ICH) E14 Guidance] [17]. In pre-clinical studies, supra-
therapeutic dabigatran [up to 3 mg/kg intravenously; nearly
100 times the median effective dose (ED50)] had no
influence on cardiovascular parameters [18]. In isolated
guinea pig papillary muscles, no noteworthy changes in QT
interval were observed with dabigatran stimulation [con-
centrations up to 10 lmol/L, approximately 2,000-fold the
inhibition constant (Ki) for thrombin], indicating a lack of
effect on cardiac ion channels [19]. As blockade of the
human Ether-a`-go-go-Related Gene (hERG)-mediated
potassium current is the most common mechanism of drug-
induced prolongation of the myocardial action potential
and QT-interval prolongation, data showing that dabigatran
did not modify the hERG-mediated potassium current in
human embryonic kidney cells agree with the previously
mentioned pre-clinical results [20]. Taken together, these
results suggest that dabigatran does not prolong QT inter-
vals in pre-clinical evaluations.
Studies to evaluate the effects of drugs on cardiac
repolarization and the QT interval are designed to detect
modest changes on the ECG. Consequently, they are gen-
erally randomized, conducted in healthy subjects, and
include a placebo and an active positive-control group. The
current study was performed specifically to assess the
electrophysiological effects of clinical and supratherapeutic
doses of dabigatran etexilate (150 mg and 600 mg,
respectively) compared with placebo and the active control
moxifloxacin in healthy subjects. It was conducted in 2006
as part of the clinical development of dabigatran etexilate
and was previously published as an abstract and presented
as a poster at the American College of Cardiology Scientific
Sessions in 2011.
2 Materials and Methods
2.1 Study Design and Randomized Treatments
This was a randomized, placebo-controlled, four-treatment,
four-period crossover study. Dabigatran etexilate 150 mg or
600 mg, or placebo, was administered in a double-blind,
double-dummy manner (as four capsules, using a combina-
tion of placebo and/or dabigatran etexilate 150-mg capsules
as appropriate). The positive control (400 mg moxifloxacin,
Avelox; Bayer Vital, Leverkusen, Germany) was given as
one open-label capsule.
Study medication was administered with 240 mL of water
following an overnight fast of at least 10 h. A washout of at
least 5 days between subsequent visits was required
(Fig. 1a). All participants were kept under medical surveil-
lance for 24 h post-dose. Breakfast, a light lunch and dinner
were provided 1.5, 4 and 10 h post-dose, respectively, and an
optional light snack was offered 7 h post-dose (all after ECG
recordings and PK samples were taken).
The four treatments were included in 12 sequences
based on three orthogonal Williams’s squares, as recom-
mended for thorough QT studies because it is variance
balanced and adjusts for potential carryover effects [21,
22]. This design ensures double-blind conditions for pla-
cebo and dabigatran etexilate treatments, while allowing
for open-label administration of moxifloxacin.
The active control was included to demonstrate that the
study had adequate sensitivity to detect a small, but sig-
nificant, drug-induced QT-prolonging effect. Moxifloxacin
produces a modest QT-interval prolongation (8–14 ms)
after a single dose [23] and is the most commonly used
positive control [24, 25]. Its peak plasma concentration
occurs 1–4 h following an oral dose without food and its
PK half-life is about 12 h.
The clinical trial protocol and other relevant study
documents were reviewed and approved on 21 February
2006 by the responsible ethics committee: Ethikkommis-
sion der Landesa¨rztekammer Baden-Wu¨rttemberg, Jah-
nstraße 40, D-70597 Stuttgart, Germany. This trial was
performed in accordance with the protocol, the principles
laid down in the Declaration of Helsinki (1996), the ICH
Harmonised Tripartite Guideline for Good Clinical Prac-
tice (GCP) and applicable regulatory requirements. In the
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European Clinical Trials Database, this study is included as
EudraCT 2005-006154-13.
2.2 Subjects
A total of 40 healthy female and male Caucasian subjects
were recruited from the volunteer pool of the Human
Pharmacology Centre, Boehringer Ingelheim Pharma
GmbH & Co. KG, Biberach, Germany; each sex was to
represent at least one-third of the study population. All
participants provided written informed consent in compli-
ance with GCP and local laws and regulations. Subjects
aged 18–65 years with a body mass index (BMI) of
20.0–29.9 kg/m2 were screened and selected according to a
complete medical history, including physical examination,
vital signs, 12-lead ECG and clinical laboratory tests.
Subjects were excluded if they exhibited ECG values
outside the reference range for clinical relevance: heart
rate (HR) \45 beats/min (bpm) or [80 bpm; PR interval
[220 ms; QRS interval [120 ms; QT interval [470 ms;
or corrected (c) QT intervals, namely QTcF (Fridericia) or
QTcB (Bazett) [450 ms; or if they had any history of
pathological bleeding.
2.3 ECG Assessment
ECG profiles were obtained at baseline (day -1) and on the
day of treatment (day 1), at the same clock time (time
matched) within each of the four treatment periods
(Fig. 1a). ECGs were taken after subjects had rested for at
least 10 min in the supine position. ECGs were recorded in
triplicate, 30–120 sec apart, to account for inherent vari-
ability; each recording lasted 10 sec. They were performed
at pre-defined times [-0.5 (baseline), 1, 1.5, 2, 3, 6, 12 and
24 h; the last two time points were omitted for moxiflox-
acin (Fig. 1b)]. The time point -0.5 was used as the time-
matched baseline for the 24-h time point. ECGs were
recorded digitally, in compliance with regulatory guidance
for annotated digital ECGs [17], using a Corina Cardio-
Soft electrocardiograph (ECG) and MUSE CV cardiology
system (General Electric Medical Systems, Freiburg,
Germany). ECG readings were sent electronically to a
central laboratory for semi-automated interval measure-
ment (using manual over-read of automatically determined
fiducial interval marks) of R wave to R wave (RR), PR,
QRS and QT intervals.
For each ECG, the ECG intervals were determined from
four wave forms, preferably in lead II. Hence, the triplicate
ECG recordings resulted in data from 12 wave forms. The
average of these values formed the ECG interval endpoints
for each of the time points. The laboratory performing the
ECG interval measurements and assessments was blinded
with regard to all treatments used, including moxifloxacin,
and to timing of the ECGs.
2.4 Pharmacokinetic Evaluation
Subjects were cannulated and blood samples for dabigatran
PK measurements were collected at the same time points as
the ECG recordings (predose, 1, 1.5, 2, 3, 6, 12 and 24 h),
to investigate potential exposure-response relationships and
confirm the availability of the drug.
Plasma concentrations of free, non-conjugated dabiga-
tran, of total (free and conjugated) dabigatran (after alkaline
cleavage of conjugates) and of the pro-drug (dabigatran
etexilate) and its intermediates (BIBR1087 and BIBR
951) were analysed using a validated high-performance
liquid chromatography tandem mass spectrometry method at
Fig. 1 Elements of the study
design: (a) schedule of the
visits; (b) timing of the ECG
and pharmacokinetic
measurements. ‘Same
measurement’ refers to the ECG
recording at ‘day 1, 0.5 h’ being
used as a time-matched data
point for both ‘day -1, -0.5 h’
and ‘day 1, 24.0 h.
ECG electrocardiogram,
PK pharmacokinetic
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NUVISAN GmbH, Neu-Ulm, Germany, as previously
reported [5]. No PK measurements were taken during
moxifloxacin treatment, as the active control is used to
demonstrate assay sensitivity for the primary analysis only.
2.5 Safety Profile Evaluation
Safety was assessed by recording adverse event withdraw-
als, the incidence and intensity of adverse events, laboratory
assessments, vital signs and weight. During screening and
the end of study evaluation, vital signs were recorded after
the subject had been supine for at least 10 min. At screen-
ing, pre-dose and end-of-study, clinical laboratory param-
eters were assessed after fasting for at least 10 h.
Tolerability was investigator-assessed using adverse event
reports and laboratory evaluations, and was categorized as
‘good’, ‘satisfactory’, ‘not satisfactory’ or ‘bad’.
2.6 Study Endpoints and Statistical Considerations
2.6.1 Primary and Secondary Endpoints
As the primary parameter, the individual heart-rate–
corrected QT interval (QTcI) was chosen. The primary
endpoint was derived as the average of the QTcI values
obtained 1.5, 2 and 3 h post-dose minus the average of the
time-matched QTcI values obtained at baseline (day -1) in
each study period. Plasma levels of dabigatran and moxiflox-
acin were expected to be at least 75 % of their peak during this
period, which thus represented the highest expected exposure.
The null hypothesis was that the difference between each of
the two doses of dabigatran etexilate (150 mg and 600 mg) and
placebo for mean change from baseline (CfB) for the QTcI
was greater than or equal to 10 ms, according to regulatory
guidance [17]. This test was performed one-sided at the 5 %
significance level, which is equivalent to the upper limit of the
two-sided 90 % confidence intervals (CIs). To conclude that
dabigatran etexilate was non-inferior to placebo, the null
hypothesis had to be rejected for both doses simultaneously;
hence no adjustment for multiple testing was necessary.
Secondary endpoints included: (i) the mean of the CfB
for QTcI from all ECGs taken from 1 to 6 h post-dose and
(ii) the time-matched CfB for QTcI at any time point
between 0.5 and 24 h post-dose.
Other parameters of interest included the other QT
correction formulas (study population, QTcN; Fridericia,
QTcF; Bazett, QTcB, see below). In addition, the uncor-
rected QT interval and heart rate were analysed. All
inferential analyses were performed separately for all of
these parameters, while the primary emphasis was the
evaluation of the QTcI endpoints.
Notable changes post-baseline in QTcI, QTcN, QTcF,
QTcB or the uncorrected QT interval were assessed using
the thresholds in compliance with regulatory guidance [17]:
the new onset of QTc greater than 450, 480 or 500 ms
post-baseline, time-matched CfB of QTc of greater than 30
or 60 ms, and new onset of QT interval greater than 500 ms.
2.6.2 Heart Rate Correction Models
Changes in heart rate can influence QT interval length.
Furthermore, heart rate correction should be performed to
improve the accuracy for detecting drug-induced QT pro-
longation and to overcome potential effects of diurnal
variation [26]. We used an individual heart rate correction
derived from all baseline log-transformed QT and RR
interval data for each subject.
The general formula is:
QTc½ms ¼ ð1000=RR½msÞslope  QT½ms
The slope was determined using a multi-level model
including subject and period as factors that accounted for
potential differences between the baseline periods [27]. For
the individual correction QTcI, the slopes were determined
individually, while for the population correction QTcN,
one study population slope was derived. QTcF (QT/RR1/3)
and QTcB (QT/RR1/2) were also determined.
2.6.3 Statistical Models
The primary endpoint (average of the time-matched CfB of
the QTcI between 1.5 and 3 h post-dose) for placebo and
both doses of dabigatran etexilate was evaluated using an
analysis of covariance (ANCOVA) model for crossover
data. The model accounted for the following sources of
variation: ‘sequence’, ‘period’ and ‘treatment’ as fixed
effects, ‘subjects nested within sequences’ as a random
effect and ‘baseline’ as a covariate.
Analysis of secondary endpoints, time-matched CfB of
the QTcI at any time between 1 and 24 h post-dose, used
the Patterson repeated measurements model [28], which
accounts for ‘time’ as a repeated effect with an unstruc-
tured covariance matrix. All observed data were used.
All analyses were also performed similarly with regard
to moxifloxacin-induced changes in QTcI [22]. Finally, an
exposure-response analysis of the placebo-corrected time-
matched CfB of QTcI for dabigatran (with subject as a
factor and dabigatran concentration as a linear covariate)
was performed as a post hoc analysis, as proposed by
Garnett et al [29].
2.6.4 Sample Size
The sample size was determined using published recom-
mendations for a thorough QT study [30] and using
an expected variability of the primary endpoint of 9.5 ms
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[31, 32]. Based on the absence of QT effects in pre-clinical
in vivo and in vitro studies and human clinical trials, a
minimal expected difference of 1 ms between dabigatran
and placebo was selected, leading to a sample size of 36
subjects to demonstrate non-inferiority with a power of
90 %. This sample size was also sufficient to detect a
difference of 9 ms in the mean time-matched CfB of QTcI
between moxifloxacin and placebo with a power of 90 %.
To account for potential dropouts and/or unevaluable data
points, 40 subjects were included in the trial.
3 Results
3.1 Subject Demographics and Disposition
Forty subjects were enrolled, randomized and received
study medication between 23 March until 26 May 2006; all
40 completed the trial (Table 1).
3.2 Individual Heart-Rate–Corrected QTcl
3.2.1 Primary Endpoint
The primary endpoint, mean time-matched CfB of QTcI
between 1.5 and 3 h post-dose, was -4.6 ms for placebo, -
4.9 ms for dabigatran etexilate 150 mg and -5.0 ms for
dabigatran etexilate 600 mg (Table 2). The mean estimate
of the placebo-adjusted CfB was close to 0 ms; the upper
bound of the two-sided 90 % CI was 1.4 ms for dabigatran
etexilate 150 mg and 1.3 ms for dabigatran etexilate 600
mg (Fig. 2; Table 2). Hence the null hypothesis was
rejected, and this thorough QT trial demonstrated that da-
bigatran etexilate does not have a meaningful impact on the
QT interval.
3.2.2 Secondary Endpoints
The mean time-matched CfB of QTcI between 1 and 6 h
post-dose was -5.2 ms for placebo, -5.3 ms for dabigatran
etexilate 150 mg and -5.4 ms for dabigatran etexilate 600
mg. The mean estimate of the placebo-adjusted CfB of
QTcI was close to 0 ms and the upper bound of the two-
sided 90 % CI was 1.5 ms for dabigatran etexilate 150 mg
and 1.4 ms for dabigatran etexilate 600 mg (Fig. 2).
The largest time-matched CfB of the QTcI between 0.5
and 24 h post-dose was slightly negative at all times for
both dabigatran etexilate doses. The upper bound of the
two-sided 90 % CI of the largest time-matched mean dif-
ference from placebo was approximately 3 to 4 ms at both
dose levels, and all 90 % CIs were between –5 ms and 5 ms
(Table 3). Therefore, non-inferiority was also achieved in
the secondary analyses for both doses of dabigatran
etexilate.
3.2.3 Exposure-Response Analysis
The exposure-response analysis was introduced post hoc to
compare the results with those of the primary analysis. The
slope between total and free dabigatran concentration and
the placebo-corrected time-matched CfB of QTcI was close
to 0, and the 90 % CI of the predicted value of this
parameter at the geometric mean (gMean) maximum
plasma concentration (Cmax) associated with each dose was
below 3 ms for all four analyses (Table 4). Hence, the
results of the exposure-response analysis were in full
agreement with the primary and secondary endpoint
analyses.
3.2.4 Assay Sensitivity
For the positive control moxifloxacin, the mean time-
matched CfB of QTcI between 1.5 and 3 h post-dose was
9.4 ms (Table 2), leading to a placebo-adjusted CfB of
14.2 ms (90 % CI 12.3–16.2) (Fig. 2; Table 2), which was
above the margin of 5 ms defined in regulatory guidance.
The largest time-matched CfB observed 0.5–24 h post-dose
was reported at 2 h and produced a placebo-adjusted dif-
ference of 14.1 ms (90 % CI 11.4–16.7; Table 3). The time
profile of QTcI was as expected, the profile has a clear peak
(at the time of the expected maximum exposure) and a
sufficient declining phase, which are the required elements
for the positive control in a QT trial (Fig. 2). These data
confirm the assay sensitivity of this trial to detect any QT
prolongation.
Table 1 Summary of subject disposition, demographic characteris-
tics and ECG measures
Demographic Total
Randomized and treated subjects, n (%) 40 (100)




Age (y) 38.6 (7.7)
Height (cm) 173.4 (7.9)
Weight (kg) 73.0 (10.9)
BMI (kg/m2) 24.2 (2.5)
Heart rate (bpm) 62.3 (8.0)
QT interval (ms) 398.4 (28.9)
QTcI (ms) 401.1 (23.3)
Data are given as mean (standard deviation) except where indicated
otherwise
BMI body mass index, bpm beats per minute, ECG electrocardiogram,
QTcl heart-rate–corrected QT interval
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3.3 Other Parameters of Interest
3.3.1 Heart Rate, Uncorrected QT Intervals
and Additional Heart-Rate–Corrected QT Intervals
RR-interval changes were minimal and the resulting heart
rate change was less than 1 bpm. The various absolute
QT(c) endpoints and CfBs did not differ by more than 1 ms
for QTcN and QTcF from OTcI, slightly more for uncor-
rected QT and QTcB, and none of these parameters was
prolonged with either dabigatran etexilate dose.
Although no systematic changes of heart rate were
present in this study, heart rate correction formulae also
adjust for random heart rate variability. The standard errors
(and hence the widths of the CIs of the estimates) of the
other heart-rate–corrected QTc intervals were higher than
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Fig. 2 Mean (±90 % confidence interval) placebo-corrected change
from baseline of QTcI over time after dosing with dabigatran etexilate
150 mg, 600 mg and moxifloxacin 400 mg. QTcI individually heart-rate-
corrected QT interval. Dotted line is the 10 ms non-inferiority margin
Table 3 Comparison of
placebo-corrected changes from
baseline (DD) of QTcl, QT and
heart rate over time in healthy
subjects treated with dabigatran
etexilate 150 mg, dabigatran
etexilate 600 mg and
moxifloxacin 400 mg
Placebo-corrected changes from
baseline are expressed as mean
(90 % CI)
bpm beats per minute, HR heart
rate, QTcI individually heart-rate–
corrected QT interval
Time DDQTcI (ms) DDQT (ms) DDHR (bpm)
Dabigatran etexilate 150 mg (n = 40)
1:00 -0.1 (-2.5 to 2.2) -0.7 (-4.0 to -2.6) 0.7 (-0.5 to 1.8)
1:30 -1.4 (-3.2 to 0.4) -0.6 (-3.3 to 2.1) -0.3 (-1.4 to 0.8)
2:00 -0.7 (-2.9 to 1.6) -0.2 (-2.9 to 2.6) -0.3 (-1.5 to 0.8)
3:00 -1.1 (-3.3 to 1.2) -1.9 (-4.9 to 1.0) 0.6 (-0.8 to 0.2)
6:00 -0.4 (-3.0 to 2.2) -0.5 (-3.8 to 2.7) 0.1 (-1.4 to 1.2)
12:00 0.9 (-1.7 to 3.5) 1.3 (-1.8 to 4.5) -0.4 (-1.7 to 0.9)
24:00 -0.1 (-1.9 to 1.7) -0.2 (-2.8 to 2.5) -0.1 (-1.1 to 1.0)
Dabigatran etexilate 600 mg (n = 40)
1:00 -1.5 (-3.8 to 0.9) -1.8 (-5.2 to 1.5) 0.5 (-0.6 to 1.6)
1:30 -1.7 (-3.5 to 0.2) -0.6 (-3.3 to 2.1) -0.3 (-1.5 to 0.8)
2:00 -2.6 (-4.8 to -0.4) -0.9 (-3.7 to 1.8) -1.1 (-2.2 to 0.1)
3:00 -1.1 (-3.3 to 1.1) -2.9 (-5.8 to 0.1) 1.5 (-0.1 to 2.9)
6:00 -0.8 (-3.4 to 1.8) -1.1 (-4.3 to 2.2) 0.6 (-0.7 to 1.9)
12:00 0.4 (-2.2 to 3.0) 1.0 (-2.1 to 4.2) -0.2 (-1.5 to 1.1)
24:00 -1.6 (-3.4 to 0.2) -3.1 (5.7 to 0.5) 1.1 (0.0 to 2.2)
Moxifloxacin 400 mg (n = 40)
1:00 11.1 (8.4 to 13.8) 8.3 (4.7 to 11.9) 2.4 (0.9 to 3.8)
1:30 12.8 (10.2 to 15.6) 11.9 (8.3 to 15.5) 1.3 (0.1 to 2.5)
2:00 14.1 (11.7 to 16.5) 13.6 (10.4 to 16.9) 0.4 (-1.0 to 1.7)
3:00 14.1 (11.4 to 16.7) 10.3 (6.9 to 13.8) 2.7 (1.1 to 4.4)
6:00 10.4 (8.0 to 12.8) 9.2 (6.1 to 12.2) 1.5 (0.1 to 2.8)
Table 2 Difference in QTcI from baseline and from placebo between 1.5 and 3 h post-dose
Treatment n Adjusted mean (SE)
D QTcI (ms)
Mean (SE) [90 % CI]
DD QTcI (ms)
Placebo 40 -4.6 (1.1)
Dabigatran etexilate (150 mg) 40 -4.9 (1.1) -0.2 (1.0) [-1.9, 1.4]
Dabigatran etexilate (600 mg) 40 -5.0 (1.1) -0.4 (1.0) [-2.0, 1.3]
Placebo 40 -4.8 (1.0)
Moxifloxacin (400 mg) 40 9.4 (1.0) 14.2 (1.2) [12.3, 16.2]
QTcI individually heart-rate–corrected QT interval, SE standard error, D change from baseline, DD placebo-corrected change from baseline
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[33–35]. This strongly supports the use of QTcI as the
primary correction method in this study.
3.3.2 ECG Safety Evaluation and Vital Signs
There were no notable changes in any of the subjects for
heart rate or PR/QRS intervals. The overall quality of the
ECG recordings was very good because there were no
ECGs with findings impacting interval measurement.
Any findings relating to ECG or vital signs that deviated
from normal were deemed reflective of the normal varia-
tions occurring in healthy subjects.
3.4 Pharmacokinetic Results
3.4.1 Dabigatran Plasma Concentration-Time Profiles
The plasma concentrations of total (free and conjugated)
dabigatran rapidly increased following administration of
dabigatran etexilate, with Cmax at a median of 2–3 hours
(Table 5). Mean Cmax with dabigatran etexilate 600 mg
was approximately fourfold higher than that achieved with
dabigatran etexilate 150 mg (Table 5). Dabigatran etexilate
and its intermediates (BIBR1087 and BIBR951) were only
detectable between 0.5 and 3 h post-dosing and then only
in very low concentrations.
3.5 Safety and Tolerability
Single oral doses of dabigatran etexilate 150 mg and
600 mg were well tolerated in this study. Global tolera-
bility was reported as ‘good’ for all subjects and with all
treatments, except for one subject who responded ‘not
satisfactory’ after receiving moxifloxacin. A total of 21
subjects experienced at least one adverse event. All adverse
events were of mild intensity and all subjects fully recov-
ered. Five subjects reported adverse events during screen-
ing: headache (n = 3), back pain, allergic reaction (n = 1
each). During the three washout periods, adverse events
were reported on ten occasions: herpes labialis (n = 3),
headache (n = 2), flatulence, puncture-site pain, influenza-
like symptoms, hayfever, diarrhoea (n = 1 each). Within
the treatment period, adverse events were reported in three
subjects (7.5 %) receiving dabigatran etexilate 150 mg
(headache, heartburn, puncture-site haematoma) and four
(10 %) receiving dabigatran etexilate 600 mg [puncture-
site haematoma, hypermenorrhea, application-site allergy
(i.e. electrode contact site), heartburn and headache]. One
subject (2.5 %) reported ‘feeling dazed’ with moxifloxacin;
dizziness and thoracic pain was recorded for one subject
(2.5 %) receiving placebo. All bleeding events and the
moxifloxacin-related adverse events were deemed to be
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increased menstrual flow; no correlation with dabigatran
etexilate treatment was apparent. There were no deaths and
no serious or significant adverse events reported.
4 Discussion
The aim of this study was to investigate whether thera-
peutic and supratherapeutic doses of dabigatran etexilate
prolong the QT interval. Dabigatran etexilate 150 mg once
daily is the lower of two doses available for primary VTE
prevention following elective hip and knee replacement
surgery [9, 10]. Dabigatran etexilate 150 mg twice daily is
a dose approved for the prevention of stroke and systemic
embolism in patients with non-valvular AF [7, 13–15, 36].
Based on previous PK studies [36, 37], 600 mg once daily
was adopted as the supratherapeutic dose. Additionally, a
single rather than a multiple [5] supratherapeutic dose
design was adopted, allowing a higher maximum plasma
level of the drug without compromising safety. In a pilot
study, this dose resulted in a two- to threefold increase in
the main coagulation parameter (activated partial throm-
boplastin time) achieved at 2–4 h post-dose. Higher doses
were deemed inappropriate because the bleeding risk
increases dose dependently [5, 37].
The PK results confirmed that the Cmax after adminis-
tering dabigatran etexilate 600 mg was approximately
fourfold higher than that achieved with the 150-mg dose.
This Cmax is also 2.6 or 4 times higher than the steady-state
concentration in patients receiving dabigatran etexilate
150 mg twice daily (146 ng/mL) or once daily (99.2 ng/mL),
respectively [36]. Therefore, it is unlikely that the Cmax in
clinical use would usually exceed that of the suprathera-
peutic dose tested. Dabigatran etexilate has been adminis-
tered to healthy volunteers at single doses up to 400 mg and
multiple doses up to 400 mg three times daily for 6 days.
The pharmacokinetic profile of a single dose of dabigatran
etexilate predicted the steady-state pharmacokinetic profile
of dabigatran; indeed, no time-dependent changes were
observed in the pharmacokinetic profile of dabigatran after
multiple dosing, despite accumulation seen with the three-
times-daily regimen [38].
Although using single rather than multiple dosing might
be considered a limitation in the design of thorough QT
studies, a single-dose approach using a four-period cross-
over has been employed to test QT prolongation with other
medications such as rivaroxaban, a direct factor Xa
inhibitor [24], and eltrombopag, a thrombopoietin receptor
agonist [25]. The rivaroxaban QT study [24] also employed
the positive control moxifloxacin 400 mg and a placebo.
While our study used a fourfold supratherapeutic dose of
dabigatran etexilate, the rivaroxaban study used a threefold
supratherapeutic dose [24]. Whereas the population in our
study ranged in age from 24 to 53 years, the patients in the
rivaroxaban trial were at least 50 years old [24]. Although
most patients undergoing orthopaedic surgery or who have
AF tend to be over 60 years of age, dabigatran etexilate is
also being assessed for VTE treatment and these patients
are likely to cover a wider age range [9, 10]. Therefore, this
current safety study is relevant for patients who could
potentially receive dabigatran etexilate in the future.
The control, moxifloxacin, was administered as com-
mercially available capsules, with ECG recorded up to 6 h
post-dose (rather than 24 h for dabigatran) and no phar-
macokinetic sampling. Thus, treatment was double-blind
for the two doses of dabigatran etexilate and placebo and
open-label for moxifloxacin. Open-label assessment of
moxifloxacin effects is a possible limitation of the study.
Nonetheless, ECG intervals were measured in a fully
blinded fashion at a central laboratory. The laboratory was
audited to ensure that their blinding process for ECG
evaluation was carried out correctly.
The primary formula used to correct the QT interval for
heart rate was different than in other QT studies [24, 25,
39]. A study of the direct thrombin inhibitor AZD0837 in
patients with atrial flutter used the Fridericia (QTcF)
Table 5 Dabigatran pharmacokinetics after single doses of dabigatran etexilate 150 mg and 600 mg
Parameter Non-compartmental parameters of free non-conjugated
dabigatran
Non-compartmental parameters of total dabigatran (free and
conjugated)
Dabigatran etexilate 150 mg
(n = 40)
Dabigatran etexilate 600 mg
(n = 40)
Dabigatran etexilate 150 mg
(n = 40)
Dabigatran etexilate 600 mg
(n = 40)
gMean gCV (%) gMean gCV (%) gMean gCV (%) gMean gCV (%)
AUC? (ngh/mL) 540 74.3 2,230 43.5 703 71.5 3,070 42.1
Cmax (ng/mL) 71.4 80.8 281 38.5 87.8 76.8 383 38.1
tmax (h)
a 2.03 0.983–3.15 3.00 1.50–6.03 2.03 1.48–3.15 3.00 1.50–6.03
AUC? area under the plasma concentration-time curve from time zero to infinity, Cmax maximum observed plasma concentration, gCV geometric
coefficient of variation, gMean geometric mean, tmax time to reach Cmax
a For tmax, the median and range (min to max) are given
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formula [40]. Although both Fridericia and Bazett (QTcB)
correction formulas are widely used, their accuracy and use
have been criticized [41]. Thus, a formula using subject-
specific baseline data for calculating the QT interval
(QTcI) was primarily employed, similar to that used for the
rivaroxaban QT study [24]. A recent white paper on QT
interval correction in the presence of drug-induced heart
rate changes has been published since we conducted our
study [42]. Although we could have used an alternative
method of heart rate correction as the primary formula, we
have shown in our evaluation of different methods that this
would have had very limited impact on the study results.
The primary endpoint of our study demonstrated non-
inferiority for both doses of dabigatran etexilate (150 mg
and 600 mg) compared with placebo. The upper limit of the
95 % CI was approximately 1.5 ms, which was signifi-
cantly below the usual 10-ms margin for non-inferiority.
Both doses of dabigatran etexilate were also non-inferior to
placebo for the secondary endpoints. The upper limit of
95 % CI was below 4 ms, which was clearly lower than the
10-ms margin for non-inferiority. Furthermore, and as
stated in the ICH E14 Guideline, drugs that prolong the
mean QT or QTcl by around 5 ms or less do not appear to
cause torsade de pointes [17]. Results from our study show
that treatment with dabigatran etexilate does not prolong
the QT interval by more than 5 ms, hence is not expected to
treat serious cardiac pro-arrhythmias; this can therefore be
termed a negative thorough QT study.
For the positive control moxifloxacin, the mean CfB of
QTcI between 1.5 and 3 h post-dose was 9.4 ms, and 14.2
ms when compared with placebo. For all treatments and
time intervals, changes in heart rate were nominal and
within the range of ± 2.0 bpm. These findings are indic-
ative of the robustness of the QT analyses performed in this
study. The adverse events observed are consistent with
those previously reported in trials examining the tolera-
bility and safety of dabigatran etexilate at therapeutic or
fourfold supratherapeutic doses [5]. No adverse event led
to premature study discontinuation.
5 Conclusion
This study demonstrates that therapeutic (150 mg) and
supratherapeutic (600 mg) doses of dabigatran etexilate are
not associated with QT prolongation or arrhythmogenic
effects. The risk of potential events related to QT prolon-
gation or cardiac repolarization effects of dabigatran
etexilate is therefore considered to be very low.
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